The Reimbursement Code Your Medtech Startup Is Counting On Doesn't Exist Yet

You spent three years developing the device. You cleared FDA. You have a published clinical study, a real manufacturing partner, and a term sheet from a regional distributor who is genuinely excited. Then someone in your first hospital meeting asks which CPT code you're billing under, and the room goes quiet.

Photo by Mikhail Nilov on Pexels.

This is where a lot of medtech founders discover they have a product with no payment pathway. Not a regulatory problem. A reimbursement problem. And it's one of the most expensive surprises in the entire lab-to-market journey because it lands after you've spent the money.

Why Founders Get This Wrong

The FDA clearance process is hard, visible, and well-documented. There are consultants, courses, and horror stories everywhere you look. Reimbursement coding is different. It's slower, less legible, and nobody in your PhD program ever mentioned it.

Here's what actually happens: when a new procedure or device category doesn't fit neatly into an existing billing code, hospitals and physicians either can't get paid for using it or have to file under a miscellaneous code (like CPT 0999T or an unlisted procedure code). Miscellaneous codes almost always trigger manual review. Manual review means delayed payment. Delayed payment means your target customers have zero financial incentive to adopt your product, regardless of how well it works.

Some founders hear this and think, "I'll just apply for a new code." The CPT Category III process (for emerging technologies) takes roughly one to two years. Category I, which is the permanent reimbursement code that insurers actually pay against, requires substantial clinical data across multiple published studies and can take five or more years. CMS coverage determinations run on their own schedule entirely.

You will not get a code by the time your first commercial customer wants to buy.

What the Reimbursement Timeline Actually Looks Like

graph TD
    A[FDA Clearance] --> B{Existing CPT code?}
    B -- Yes --> C[Confirm payer coverage policies]
    B -- No --> D[File CPT Category III application]
    C --> E(Negotiate hospital contracts)
    D --> F[1-2 year AMA review cycle]
    F --> G[Category III code issued]
    G --> H{Payer coverage?}
    H -- No --> I[Build evidence dossier for payers]
    H -- Yes --> E
    I --> E

Notice how many steps sit between clearance and an actual paying customer. Each node on that path is measured in months, not weeks.

What You Should Do Instead of Assuming

Start your reimbursement analysis at the same time you start your regulatory strategy. Not after. The questions to answer early: Does an existing CPT code cover your procedure, even imperfectly? Which payers control the most lives in your target geography? Do those payers have coverage policies for your device category, or is it a blank page?

If you're in a category with no existing code, your commercial strategy has to account for that gap. A few approaches actually work in practice:

Target early adopters at academic medical centers. AMCs can sometimes absorb new technology through research budgets or value analysis committees that operate outside standard billing. They're slower to scale, but they give you the utilization data you'll need later.

Get a health economist involved early. Not to write a white paper for investors. To build a payer-facing economic model that shows cost offset or outcomes improvement in terms payers respond to. This document becomes the spine of your coverage dossier.

Know your MAC. Medicare Administrative Contractors process claims regionally, and their local coverage determinations (LCDs) can create a payment pathway faster than a national CMS decision. Some companies have launched commercially in two or three MAC jurisdictions while pursuing broader coverage everywhere else.

Build the reimbursement timeline into your runway model. If you're two years from a Category III code and another two from meaningful payer coverage, you need enough runway to survive that gap or a business model (direct pay, bundled payments, ASC channel) that doesn't depend on traditional fee-for-service.

The Honest Version of Your Go-to-Market

Most medtech pitch decks show a clean arc: clear FDA, sign distributors, grow revenue. The reimbursement layer gets a single slide with a CPT code listed as if it already exists.

Investors who know medtech will ask about your coding strategy in the first meeting. Hospital system buyers will ask in the first call. If your answer is vague, they'll assume you haven't done the work. Because usually, you haven't.

Get a reimbursement consultant who specializes in your procedure category before you close your seed round. Not after. The cost of that engagement is trivial compared to the cost of building a commercial team that has nowhere to sell.